CHURCHILL MANAGEMENT Corp Grows Stock Holdings in Danaher Co. (NYSE:DHR)

CHURCHILL MANAGEMENT Corp increased its stake in Danaher Co. (NYSE:DHR) by 2.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 51,111 shares of the conglomerate’s stock after purchasing an additional 1,460 shares during the quarter. CHURCHILL MANAGEMENT Corp’s holdings in Danaher were worth $11,732,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in DHR. FMR LLC grew its holdings in shares of Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after acquiring an additional 3,217,631 shares during the period. Legal & General Group Plc grew its stake in shares of Danaher by 2.4% during the 2nd quarter. Legal & General Group Plc now owns 5,964,031 shares of the conglomerate’s stock valued at $1,490,112,000 after purchasing an additional 139,989 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Danaher by 3.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock valued at $1,417,342,000 after purchasing an additional 148,251 shares during the last quarter. Fisher Asset Management LLC lifted its stake in shares of Danaher by 2.6% in the 3rd quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock worth $1,265,725,000 after purchasing an additional 116,299 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its holdings in shares of Danaher by 17.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after buying an additional 535,254 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of NYSE:DHR opened at $237.78 on Thursday. The firm has a fifty day simple moving average of $235.27 and a two-hundred day simple moving average of $253.56. Danaher Co. has a 52 week low of $222.53 and a 52 week high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $171.74 billion, a P/E ratio of 45.38, a PEG ratio of 4.32 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm’s revenue was up 3.1% on a year-over-year basis. During the same quarter last year, the business posted $2.02 earnings per share. On average, analysts expect that Danaher Co. will post 7.5 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is 20.61%.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on DHR. UBS Group lowered their target price on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Raymond James cut their price objective on Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. KeyCorp raised their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Scotiabank assumed coverage on shares of Danaher in a research report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price target for the company. Finally, Robert W. Baird decreased their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.